The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved. · v2.0

Privacy PolicyTerms of UseCookie Policy

RXRX FINANCIAL STATEMENTS

Recursion Pharmaceuticals Inc — balance sheet, income statement and cash flow trends

RXRXRecursion Pharmaceuticals Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value itDuel
PriceFinancialsPeers

Income Statement

Quarterly progression — trailing-twelve-month values
RevenueNet Income to Owners
-750 M-500 M-250 M0202120222023202420252026

Profit Funnel

Q2 2026 · TTM
Revenue54.9 M $Gross Profit-25.6 M $ · -47%Operating Income-544 M $ · -992%Pre-tax Income-523.5 M $ · -954%Net Income to Owners-518.9 M $ · -946%

Percentages are relative to revenue.

Key Figures

YoY change
Revenue54.9 M $-14.9%
Gross Profit-25.6 M $—
Operating Income-544 M $—
EBITDA-466.9 M $—
Net Income to Owners-518.9 M $—

No peer data is available for this stock.

Balance Sheet

Quarterly period-end values
Total AssetsTotal LiabilitiesEquity
0500 M1 B1.5 B202120222023202420252026

Capital Structure

Q2 2026
Total Assets1.2 B
  • Equity915 M $75%
  • Current Liabilities119.9 M $10%
  • Long-term Liabilities177.8 M $15%

Key Figures

YoY change
Total Assets1.2 B $-6.9%
Total Liabilities297.7 M $-22.3%
Total Equity915 M $-0.5%
Cash & ST Investments545.7 M $+3.3%
Total Debt61.9 M $-29.7%
Net Debt-483.8 M $—

No peer data is available for this stock.

Cash Flow Statement

Quarterly progression — trailing-twelve-month values
Operating Cash FlowCapital ExpendituresFree Cash Flow
-400 M-200 M0202120222023202420252026

Cash Flow Bridge

Q2 2026 · TTM
-400 M-200 M0-431.6 M $Operating-6.4 M $Investing375.1 M $Financing-62.9 M $Net Change

Key Figures

YoY change
Operating Cash Flow-431.6 M $—
Capital Expenditures2 M $-81.7%
Free Cash Flow-433.6 M $—
Dividends Paid——

No peer data is available for this stock.

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on RXRX

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Sep 3, 26. This content is for informational purposes only and is not investment advice.